

## **Invitation to presentation of Q-linea's Interim report Q3-2020 on November 5, 2020**

**Q-linea AB (publ) (Nasdaq Stockholm: QLINEA)**, to publish the company's interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET.

Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 5, 2020, at 1:00 – 2:00 p.m CET.

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q3 interim report followed by a Q&A-session.

To participate, please call any of the following phone numbers from:

Sweden: + 46 8 566 427 04

UK: + 44 333 300 9268

US: + 1 833 249 8403

Webcast: <https://tv.streamfabriken.com/q-linea-q3-2020>

### **For more information, please contact:**

Anders Lundin, CFO, Q-linea AB

[Anders.Lundin@qlinea.com](mailto:Anders.Lundin@qlinea.com)

+46 (0)70-600 15 20

*The information was submitted for publication, through the agency of the contact person set out above, at 13:30 CET on October 29, 2020.*

### **About Q-linea**

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product AStar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).